Reclast (Zoledronic Acid) Pediatric (Under 12) Dosing

At a glance

• FDA status / Reclast is not indicated for use in children
• Evidence base / small pediatric trials, cohorts, institutional protocols, and one FDA-described active-controlled study
• Common research regimen / 0.05 mg/kg IV every 6 months in selected pediatric populations
• Lower first exposure / 0.0125 mg/kg has been studied to reduce hypocalcemia
• Universal pediatric maximum / none established by the FDA label; some specialty protocols cap a dose at 4 mg
• Infusion time / pediatric studies and the label's pharmacokinetic subset used 30 minutes
• First-dose reactions / fever, pain, vomiting, hypocalcemia, and hypophosphatemia can occur
• Before treatment / confirm true skeletal fragility, calcium and vitamin D adequacy, renal status, and the exact center protocol
• Treatment target / fewer fragility fractures, vertebral reshaping during growth, pain or mobility improvement, and an appropriate BMD trajectory
• Not enough by itself / a low DXA Z-score without fracture context

Is There a Standard Zoledronic Acid Dose for a Child Under 12?

No. The current Reclast prescribing information states that Reclast is not indicated for children [1]. It describes pediatric safety and pharmacokinetic data, and the FDA clinical-pharmacology review provides additional detail about the severe-OI study, but neither creates an approved pediatric dose, interval, maximum, or treatment duration [14].

This makes the question different from adult osteoporosis dosing. The adult 5 mg once-yearly regimen should not be scaled down automatically by body weight. Children differ in growth, bone turnover, underlying disease, fracture patterns, kidney assessment, and the potential to recover bone strength when a temporary risk factor resolves [2].

Published pediatric regimens are not identical:

• Some osteogenesis imperfecta studies used 0.05 mg/kg every six months [3].
• A randomized pediatric glucocorticoid-induced osteoporosis trial used 0.05 mg/kg every six months in children aged 5 to 17 with vertebral fractures [4].
• An early safety study evaluated 0.0125 mg/kg as the initial dose and found less hypocalcemia than had been reported with higher first doses [5].
• Other trials divided or repeated doses on different schedules, reflecting diagnosis, age, and study design rather than a settled universal standard [6].

The correct interpretation is that 0.0125, 0.025, and 0.05 mg/kg are doses found in pediatric evidence and specialty protocols. They are not interchangeable menu choices for unsupervised calculation.

Who Is Considered for Off-Label Treatment?

Osteogenesis Imperfecta

Zoledronic acid is used most often in children with osteogenesis imperfecta who have recurrent long-bone or vertebral fractures, bone pain, vertebral compression, or impaired mobility. The goal is not simply to raise a DXA number. It is to reduce skeletal morbidity while growth provides an opportunity for vertebral reshaping and improved bone geometry [2].

Evidence supports increased lumbar-spine bone mineral density during treatment, but the relationship between BMD gain and fracture reduction is not perfectly predictable. The FDA label notes that BMD changes in its severe-OI pediatric study did not necessarily correlate with fracture risk or chronic bone pain [1]. A 2024 systematic review likewise found encouraging BMD results but emphasized the limits of small and heterogeneous studies [7].

Glucocorticoid-Induced Osteoporosis

Children receiving systemic glucocorticoids can develop vertebral fractures even when DXA values are not extremely low. In pediatric glucocorticoid-induced osteoporosis, spine imaging and fracture context are central because vertebral fractures may be asymptomatic and BMD alone can miss clinically important fragility [2,8].

The randomized phase 3 zoledronic acid trial enrolled children who already had low-trauma vertebral fractures. It should not be generalized to every child taking steroids or to prophylactic treatment based solely on duration of glucocorticoid exposure [4].

Other Causes of Bone Fragility

Small studies and specialty-center reports include children with immobility, neuromuscular disease, inflammatory disease, or other secondary osteoporosis. These groups differ in turnover, recovery potential, mobility, nutrition, puberty, and underlying treatment. A regimen used in OI may be too frequent or otherwise inappropriate for a child with a temporary secondary cause [2,9,15].

Confirm the Diagnosis Before Calculating a Dose

In children, osteoporosis is not diagnosed from a DXA Z-score alone. Vertebral compression fractures can establish clinically important fragility in the right setting, and fracture history, trauma mechanism, growth, pubertal stage, body size, and the underlying disease all affect interpretation. The International Society for Clinical Densitometry's pediatric positions stress using appropriate pediatric DXA sites and reference data and interpreting imaging within the child's clinical context [8].

Before a bisphosphonate is selected, evaluation generally asks:

1. Is there a vertebral fracture or a clinically significant long-bone fracture history?
2. Is the skeletal threat ongoing, or is spontaneous recovery likely when the illness or glucocorticoid exposure improves?
3. Are calcium, phosphate, vitamin D, renal function, nutrition, mobility, and pubertal development being addressed?
4. Is the child short for age, requiring size-aware DXA interpretation?
5. Is there a genetic, inflammatory, endocrine, renal, gastrointestinal, malignant, or medication-related cause that changes management?

This step protects against treating a number while missing the reason a child's bones are fragile.

How Specialists Select the First and Later Doses

First Exposure

First-infusion reactions are more frequent in bisphosphonate-naive children. A study of 63 children found that an initial 0.0125 mg/kg dose reduced hypocalcemia compared with earlier experience at 0.02 to 0.025 mg/kg, although flu-like symptoms still occurred [5]. A large institutional series also found that adverse events were concentrated around early infusions and that hypophosphatemia, acute-phase reactions, and hypocalcemia were the most common short-term findings [10].

For this reason, many pediatric protocols use a reduced first dose, especially in young or bisphosphonate-naive patients. The exact next dose and timing vary. They should come from the treating center's written protocol rather than from a single universal table [9,11].

Maintenance Exposure

The most frequently published maintenance regimen for pediatric osteoporosis is 0.05 mg/kg every six months, often with a center-specific cap. It was used in the mild-OI cohort and in the randomized pediatric glucocorticoid trial [3,4]. Other programs use 0.025 mg/kg, extend the interval, or reduce exposure as BMD and fracture status improve [9].

More treatment is not automatically better. Zoledronic acid binds bone and has a long skeletal residence. Children with growth remaining can accumulate visible metaphyseal lines after repeated exposure, and the long-term consequences of high cumulative dosing are less certain than short-term laboratory responses [1,9].

Maximum Dose

Several pediatric specialty protocols and studies cap individual doses at 4 mg. That is an institutional or study convention, not an FDA-approved pediatric maximum. The adult Reclast label limits a single adult dose to 5 mg, but that adult rule does not create a pediatric dosing recommendation [1,9].

Pre-Infusion Safety Review

Mineral Status

Hypocalcemia and hypophosphatemia are predictable early risks. The child's calcium, phosphate, magnesium when clinically indicated, and 25-hydroxyvitamin D should be reviewed and deficiencies corrected before treatment. The evidence supports vitamin D sufficiency and adequate calcium intake, but it does not support one universal supplement dose for every child because age, diet, body size, malabsorption, kidney disease, and baseline values differ [9,10].

The old practice of copying a fixed 500 to 1,000 mg calcium dose or a high-dose vitamin D repletion schedule into every pediatric plan is unsafe. Supplementation should follow pediatric nutrition and deficiency treatment standards, then be adapted to the infusion protocol.

Kidney Function and Hydration

Zoledronic acid is eliminated intact through the kidney. The adult Reclast label contraindicates use at creatinine clearance below 35 mL/min and in acute renal impairment, but it does not validate applying that adult Cockcroft-Gault threshold to every child [1]. Pediatric kidney assessment uses age-appropriate methods, often an estimated glomerular filtration rate based on a pediatric equation, interpreted by the specialty team.

Dehydration, fever, gastrointestinal losses, kidney disease, and nephrotoxic drugs can increase renal risk. An infusion should not proceed merely because a months-old creatinine value was normal. Current clinical status and the center's pre-infusion renal criteria matter [1].

Medication and Dental Review

The Reclast label advises caution with aminoglycosides, loop diuretics, nephrotoxic drugs, and other agents that can affect mineral balance or renal function [1]. The medication list should be reviewed for the child's actual risks rather than applying a generic interaction list.

Medication-related osteonecrosis of the jaw is rare in pediatric non-oncology experience, and no cases occurred in the one-year pediatric study described in the label. That does not make the risk zero. Existing dental infection, planned invasive dental treatment, oncology exposure, and cumulative antiresorptive therapy should be discussed with the treating teams [1].

Infusion and Observation

The pediatric pharmacokinetic subset in the current label received 0.05 mg/kg over 30 minutes. Pediatric studies and protocols commonly use a 30-minute infusion, longer than the adult label minimum of 15 minutes [1,9]. Product selection, dilution, final concentration, tubing, compatible fluids, and observation should follow the hospital pharmacy's pediatric protocol.

The adult product must not be mixed with calcium-containing infusion solutions. Hydration should be appropriate for the child's size and cardiac or renal status. A fixed liter or milliliter target copied from an adult handout is not appropriate for all children [1].

Many centers use acetaminophen or ibuprofen around the first infusion to reduce fever and pain, but the choice and dose should account for age, kidney status, liver status, hydration, and other medicines. A quality-improvement project showed that a standardized pediatric protocol can improve pre-infusion screening and management of common first-dose reactions [11].

What Happens After the First Infusion?

In the FDA-described pediatric trial, reactions reported more often in children included fever in 61%, arthralgia in 26%, hypocalcemia in 22%, and headache in 22%. Except for arthralgia, these were most frequent within three days of the first infusion and became less common with repeat dosing [1].

Families need specific instructions for fever, vomiting, reduced intake, muscle cramps, tingling, weakness, breathing difficulty, reduced urine output, or severe pain. Children at higher risk of mineral disturbance may need post-infusion calcium, phosphate, or other testing based on the center's protocol and symptoms [9,10].

There is no evidence-based rule that every standard-risk child needs creatinine at exactly 48 hours and again at two weeks. Monitoring should be risk-based. Inventing a universal threshold such as a 0.5 mg/dL creatinine rise for all ages can also mislead because the same absolute change has very different meaning in a toddler and an adolescent.

What Benefits Are Supported by Evidence?

Bone Density

Across pediatric OI studies, zoledronic acid generally increases lumbar-spine BMD and suppresses bone turnover. In 17 children with mild OI receiving 0.05 mg/kg every six months, median lumbar-spine BMD Z-score improved over two years, although 2 children developed symptomatic hypocalcemia [3]. A small randomized comparison with pamidronate also found improved BMD in both groups [6]. A 2024 prospective comparison found BMD gains after zoledronic acid as well, while answering a different question about comparison with denosumab rather than establishing one preferred zoledronic acid schedule [16].

Fractures and Function

Fracture outcomes are harder to interpret because many studies are small, uncontrolled, or mix disease severity and age. A two-year trial comparing once-yearly zoledronic acid with alendronate reported fewer clinical fractures with zoledronic acid, but its fixed 5 mg regimen should not be extrapolated automatically to younger or smaller children [12].

A 2025 network meta-analysis of randomized pediatric OI trials found that bisphosphonates improved BMD outcomes, while fracture evidence remained limited and zoledronic acid had higher adverse-event rates than placebo in the available network [13]. This supports careful selection and monitoring, not the claim that a higher BMD gain guarantees fracture prevention.

Glucocorticoid-Induced Osteoporosis

In the 34-child randomized phase 3 trial, zoledronic acid improved lumbar-spine BMD Z-score more than placebo at 12 months. All participants had vertebral fractures at enrollment, making this evidence most relevant to children with established skeletal fragility rather than those with glucocorticoid exposure alone [4].

Duration, Redosing, and Stopping

There is no universal two-year or three-year course for children under 12. Redosing decisions should integrate new fractures, vertebral shape, pain, mobility, growth, pubertal progress, the status of the underlying disease, BMD trajectory, bone turnover when useful, and cumulative exposure [2,9].

When the skeletal threat is transient, a growing child may recover bone strength after glucocorticoids stop, mobility improves, or inflammation is controlled. Continuing potent antiresorptive treatment after the indication has resolved can add exposure without a clear target. In severe genetic bone fragility, treatment may be longer but still needs planned reassessment.

Zoledronic acid does not require a pharmacologic taper. The relevant question is whether and when another infusion is justified. Extending the interval or stopping further doses is different from tapering a daily medicine.

Questions to Ask the Pediatric Bone Team

• What fracture or imaging finding makes treatment appropriate now?
• Is the regimen based on OI, glucocorticoid-induced osteoporosis, or another condition?
• Is this the child's first bisphosphonate exposure, and will the first dose be reduced?
• What exact dose cap and infusion concentration does this center use?
• Which calcium, phosphate, vitamin D, and kidney criteria must be met?
• What symptoms and laboratory changes are expected during the first 72 hours?
• How will benefit be measured beyond a DXA number?
• What finding would delay the next infusion, reduce exposure, extend the interval, or stop treatment?

Bottom Line

Zoledronic acid can be useful for selected children with serious bone fragility, but "Reclast dosing under 12" is not a single calculation. Reclast is not FDA-indicated for children. The pediatric literature includes 0.05 mg/kg regimens and lower first doses such as 0.0125 mg/kg, but the evidence spans different diseases, ages, and study designs.

The strongest plan begins with a verified pediatric osteoporosis diagnosis, uses a written metabolic-bone protocol, lowers first-dose risk, checks mineral and renal status, and measures fracture-centered benefit over time. It does not copy the adult 5 mg regimen, treat a DXA score in isolation, or present one weight table as an approved pediatric standard.

References

1. DailyMed. Reclast (zoledronic acid) full prescribing information. https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=5a9b3737-9ce6-4a89-b76e-6aab79eba9cf

2. Ward LM. A practical guide to the diagnosis and management of osteoporosis in childhood and adolescence. Front Endocrinol. 2024;14:1266986. https://pubmed.ncbi.nlm.nih.gov/38374961/

3. Vuorimies I, Toiviainen-Salo S, Hero M, Mäkitie O. Zoledronic acid treatment in children with osteogenesis imperfecta. Horm Res Paediatr. 2011;75(5):346-353. https://pubmed.ncbi.nlm.nih.gov/21293106/

4. Ward LM, Choudhury A, Alos N, et al. Zoledronic acid versus placebo in pediatric glucocorticoid-induced osteoporosis: a randomized, double-blind, phase 3 trial. J Clin Endocrinol Metab. 2021;106(12):e5222-e5235. Zoledronic Acid vs Placebo in Pediatric Glucocorticoid-induced Osteoporosis: A Randomized, Double-blind, Phase 3 Trial

5. Munns CF, Rajab MH, Hong J, et al. Acute phase response and mineral status following low-dose intravenous zoledronic acid in children. Bone. 2007;41(3):366-370. https://pubmed.ncbi.nlm.nih.gov/17574945/

6. Barros ER, Saraiva GL, de Oliveira TP, Lazaretti-Castro M. Safety and efficacy of one-year zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab. 2012;25(5-6):485-491. https://pubmed.ncbi.nlm.nih.gov/22876543/

7. Mahmoud I, Bouden S, Sahli M, et al. Efficacy and safety of intravenous zoledronic acid in pediatric osteogenesis imperfecta: a systematic review. J Pediatr Orthop B. 2024;33(3):283-289. https://pubmed.ncbi.nlm.nih.gov/37339526/

8. Weber DR, Boyce A, Gordon C, et al. The utility of DXA and vertebral fracture assessment in the pediatric population: 2019 ISCD official position. J Clin Densitom. 2019;22(4):567-589. The Utility of DXA Assessment at the Forearm, Proximal Femur, and Lateral Distal Femur, and Vertebral Fracture Assessment in the Pediatric Population: 2019 ISCD Official Position

9. George S, Weber DR, Kaplan P, et al. Zoledronic acid in pediatric metabolic bone disorders. Transl Pediatr. 2017;6(4):295-303. https://pmc.ncbi.nlm.nih.gov/articles/PMC5682380/

10. Bowden SA, Mahan JD. Short-term safety of zoledronic acid in young patients with bone disorders: an institutional experience. J Clin Endocrinol Metab. 2015;100(11):4163-4171. https://pmc.ncbi.nlm.nih.gov/articles/PMC4702447/

11. Weber DR, et al. A quality-improvement project to address the challenges surrounding zoledronic acid use in children. J Bone Miner Metab. 2021;39(4):693-699. https://pubmed.ncbi.nlm.nih.gov/33825940/

12. Lv F, Liu Y, Xu X, et al. Zoledronic acid versus alendronate in children with osteogenesis imperfecta: a two-year clinical study. Endocr Pract. 2018;24(2):179-188. https://pubmed.ncbi.nlm.nih.gov/29466057/

13. Wang X, et al. Optimizing bone health with bisphosphonate therapies in pediatric osteogenesis imperfecta: a network meta-analysis of randomized trials. Osteoporos Int. 2025. https://pubmed.ncbi.nlm.nih.gov/40047985/

14. U.S. Food and Drug Administration. Office of Clinical Pharmacology review: zoledronic acid in pediatric severe osteogenesis imperfecta. https://www.accessdata.fda.gov/drugsatfda_docs/pediatric/021223_Zoledronic_Acid_Clinpharm_BPCA.pdf

15. Rianthavorn P, et al. Safety and efficacy of intravenous zoledronic acid in pediatric osteoporosis. Pediatr Endocrinol Rev. 2009. https://pubmed.ncbi.nlm.nih.gov/19344075/

16. Liu J, et al. Safety and efficacy of denosumab in children with osteogenesis imperfecta: the first prospective comparative study. J Clin Endocrinol Metab. 2024;109(7):1827-1836. https://pubmed.ncbi.nlm.nih.gov/38198649/